Concepedia

Michael Smith

MS

Statistics

Publications

9

Citations

390

H-Index

9

Active since

2021

Affiliations

University of California, San Francisco(Current)

University of Colorado Anschutz Medical Campus

Heinrich Heine University Düsseldorf

National Cancer Center

Medical University of Vienna

Michael Smith is an author at University of California, San Francisco specializing in neurology, neuroimmunology, and life sciences.

ORCID

Publications per year

2021–2024

9

Publications

9

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

Orhan Aktaş, Michael Smith, William A. Rees et al. · Annals of Neurology · 2021 · 136 citations · Full text

, , +16

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

Bruce Cree, Ho Jin Kim, Brian G. Weinshenker et al. · The Lancet Neurology · 2024 · 52 citations

, , +4

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

Orhan Aktaş, Hans‐Peter Hartung, Michael Smith et al. · Journal of Neurology Neurosurgery & Psychiatry · 2023 · 45 citations · Full text

, , +17

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial

Jeffrey L. Bennett, Orhan Aktaş, William A. Rees et al. · EBioMedicine · 2022 · 42 citations · Full text

, , +17

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim et al. · Neurology Neuroimmunology & Neuroinflammation · 2021 · 39 citations · Full text

, , +9

1–5 of 9